Navigation Links
ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009
Date:10/19/2009

Appenzell, Switzerland, October 19, 2009 / b3c newswire / - ERGONEX Pharma received one of the prestigious European Orphan Diseases Entrepreneurial Company Award on the occasion of Frost & Sullivan's '2009 Excellence in Healthcare Awards Banquet,' held in London on 8th October 2009. The highly competitive award was presented to ERGONEX Pharma in recognition of the company's innovative therapeutic concept, its impressive display of technological know-how and targeted vision.

ERGONEX Pharma is focused on the clinical development and commercialisation of Terguride for the treatment of distinct orphan diseases. Terguride is currently being evaluated for the treatment of pulmonary arterial hypertension (PAH) in a Phase II trial in Europe and headline results are expected in 2010.

Dr. Rudolf Reiter, CEO of ERGONEX Pharma comments: "This award comes at an exciting and challenging time for ERGONEX Pharma. I see it as recognition of the vision, the commitment and work of the company, which would not have been possible without the continued support, expertise and out-of-the-box thinking of our partners in the on-going clinical trial. We believe that Terguride has the potential to contribute a new quality to emerging combination therapies for patients, who do not tolerate, have become resistant to or are insufficiently controlled by current treatment options in PAH.

The Frost & Sullivan Healthcare Awards Banquet honours Europe's best healthcare companies for their achievements over the course of this year. Frost & Sullivan's highly competitive awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

About Pulmona
'/>"/>

b3c newswire

Page: 1 2

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
3. Science survey ranks top biopharma employers
4. Jean-Pol Tassin wins the 2009 ECNP Neuropsychopharmacological Award
5. Researchers prolong the half-life of biopharmaceutical proteins
6. UA pharmacy research shows prescribers miss potentially dangerous drug pairs
7. 22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey
8. 22nd Congress of the European College of Neuropsychopharmacology
9. Simulating pharmaceutical and personal care product transport
10. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
11. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... A mother,s iron deficiency early in pregnancy may have ... the child, even if the lack of iron is not ... Rochester Medical Center study published in the scientific journal ... might not notice or treat mild or moderate iron deficiency, ...
... 2011) - An animal,s behavior is probably its ... Its behavior involves processes internal to the animalgenetics, neurobiology, ... social surroundings. According to the book,s authors, "Animal behavior ... sparked when neurons fire in response to stimuli in ...
... In recent years, researchers have worked to develop more ... in Afghanistan or Iraq with missing arms or legs. ... entering the body through the space where the device ... area) where the bacteria would enter the body, and ...
Cached Biology News:Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3New book on animal behavior provides integrated view 2Nanomodified surfaces seal leg implants against infection 2
(Date:4/23/2015)... Prospects for Leading Companies in ... Details   We predict the global healthcare ... in 2015 and will grow at a CAGR of 6.3% ... around the world and increasing functional requirements for healthcare packaging ... global healthcare packaging market. A global ageing population, ...
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... , April 23, 2015  Propanc Health Group ... company, focuses on the development of cancer treatments ... company lead product includes PRP, a patented formulation ... chymotrypsinogen, as well as the enzyme amylase designed ... developing a combination of anti-cancer agents working in ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) precisely measure ... in real time, and this data is uploaded to ... Machine to Machine (M2M) communications for the Internet of ... can be monitored by a patient’s clinician 24/7, ... a minimum threshold, the patient can be notified immediately. ...
Breaking Biology Technology:Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... Nov. 20 Amicus Therapeutics,(Nasdaq: FOLD ) today ... will present a corporate update at the Lazard Capital,Markets ... Tuesday,November 27th at 11:30 am ET at The New ... of the presentation will be available to all,interested parties ...
... Massachusetts and RAMBOUILLET, France,November 20 ... model-based,vision software for musculoskeletal radiography, and ... High Resolution Digital Radiology for osteoarticular,imaging, ... joint and bone,tissues, announced today the ...
... Completion of Strategic Acquisition Reflected in Q3 Results, ... Board: ECTE) today announced financial results for the,third quarter ... 30,2007, net loss was $8,677,000 or $.70 per share, ... period in 2006. For the nine months ended,September 30, ...
Cached Biology Technology:Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3Rapid Quantification of Osteoarthritis With a Novel, Office-Based, High-Resolution Digital Imaging Device 2Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
... Peptide Display Cloning System facilitates the display ... of bacteriophage M13 as coat protein fusions, ... peptide and its encoding DNA sequence. Peptide ... then be selected by the straightforward method ...
... protein Vtg in plasma from juvenile or male ... endocrine disrupting chemicals (EDCs) with estrogenic effects in ... screening test for the estrogenic effects of EDCs ... is a double-antibody immunometric (sandwich) EIA for analyzing ...
... PEP-055 is a 20 amino acid synthetic peptide whose sequence ... this peptide is (amino to carboxy terminus): V115 - L ... S - P - Q - V - P - N ... E133 (C) (The C-terminal cysteine has been added to facilitate conjugation ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: